Literature DB >> 17030912

Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA.

Hongling Guo1, Qihui Seet1, Steven Denkin1, Linda Parsons2, Ying Zhang1.   

Abstract

Drug-resistant tuberculosis poses a significant problem for treatment. The mechanisms of resistance to the front-line drug isoniazid (INH) are complex and can be mediated by katG, inhA and other unknown genes. To identify the percentage of INH-resistant strains with no katG or inhA mutation, this study characterized a panel of 28 clinical isolates of Mycobacterium tuberculosis and five mutants derived from H37Rv resistant to INH. Seventeen of 33 resistant strains (51 %) had katG mutations with 12 of the 17 strains having the most common KatG Ser315Thr mutation. Three of the 17 strains with the KatG 315 mutation had an additional mutation in the inhA promoter and were resistant to a high level of INH. Seventeen of the 33 INH-resistant strains (51 %) had inhA mutations. The most common inhA promoter mutation was -15C-->T and was present in 13 of the 17 inhA mutations. This promoter mutation occurred alone without katG mutations and was associated with a low level of INH and ethionamide resistance. However, other inhA mutations were associated with katG mutations. No mutations were found in the ndh gene. Three of 33 strains (9 %) had no mutations in katG, inhA or ndh, indicating that their resistance was due to a new mechanism of resistance. Detection of the KatG Ser315Thr mutation and the -15C-->T inhA mutation accounted for 76 % (25/33) of the INH-resistant strains and should be useful for rapid detection of INH-resistant strains by molecular tests.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17030912     DOI: 10.1099/jmm.0.46718-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  38 in total

1.  Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries.

Authors:  Kanchan Ajbani; Shou-Yean Grace Lin; Camilla Rodrigues; Duylinh Nguyen; Francine Arroyo; Janice Kaping; Lynn Jackson; Richard S Garfein; Donald Catanzaro; Kathleen Eisenach; Thomas C Victor; Valeru Crudu; Maria Tarcela Gler; Nazir Ismail; Edward Desmond; Antonino Catanzaro; Timothy C Rodwell
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs.

Authors:  Sophia B Georghiou; Marva Seifert; Donald G Catanzaro; Richard S Garfein; Timothy C Rodwell
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

3.  Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  F Brossier; N Veziris; C Truffot-Pernot; V Jarlier; W Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

4.  Genotypic and phenotypic characteristics of tunisian isoniazid-resistant Mycobacterium tuberculosis strains.

Authors:  Alya Soudani; Sondess Hadjfredj; Meriem Zribi; Feriel Messaadi; Taieb Messaoud; Afef Masmoudi; Mohamed Zribi; Chedlia Fendri
Journal:  J Microbiol       Date:  2011-06-30       Impact factor: 3.422

5.  Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis.

Authors:  Shuo Zhang; Jiazhen Chen; Peng Cui; Wanliang Shi; Wenhong Zhang; Ying Zhang
Journal:  J Antimicrob Chemother       Date:  2015-06-04       Impact factor: 5.790

6.  Diagnostic Accuracy and Utility of FluoroType MTBDR, a New Molecular Assay for Multidrug-Resistant Tuberculosis.

Authors:  Margaretha de Vos; Brigitta Derendinger; Tania Dolby; John Simpson; Paul D van Helden; John E Rice; Lawrence J Wangh; Grant Theron; Robin M Warren
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

7.  Direct inhibitors of InhA are active against Mycobacterium tuberculosis.

Authors:  Ujjini H Manjunatha; Srinivasa P S Rao; Ravinder Reddy Kondreddi; Christian G Noble; Luis R Camacho; Bee H Tan; Seow H Ng; Pearly Shuyi Ng; Ng L Ma; Suresh B Lakshminarayana; Maxime Herve; Susan W Barnes; Weixuan Yu; Kelli Kuhen; Francesca Blasco; David Beer; John R Walker; Peter J Tonge; Richard Glynne; Paul W Smith; Thierry T Diagana
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

8.  Drug resistant Mycobacterium tuberculosis of the Beijing genotype does not spread in Sweden.

Authors:  Solomon Ghebremichael; Ramona Groenheit; Alexandra Pennhag; Tuija Koivula; Emmi Andersson; Judith Bruchfeld; Sven Hoffner; Victoria Romanus; Gunilla Källenius
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

9.  First Evaluation of GenoType MTBDRplus 2.0 Performed Directly on Respiratory Specimens in Central America.

Authors:  Fedora Lanzas; Thomas R Ioerger; Harita Shah; William Acosta; Petros C Karakousis
Journal:  J Clin Microbiol       Date:  2016-07-20       Impact factor: 5.948

10.  Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance.

Authors:  Indra L Bergval; Anja R J Schuitema; Paul R Klatser; Richard M Anthony
Journal:  J Antimicrob Chemother       Date:  2009-07-04       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.